Cryptosporidium sp. and Blastocystishominis Findings: A cross-sectional Study among Healthy Versus Immunocompromised Individuals
DOI:
https://doi.org/10.61841/yf3cv969Keywords:
Immunocompromised, HIV, Intestinal Protozoa, ParasiteAbstract
Background: Cryptosporidium sp. and Blastocystishominis are widely recognized as opportunistic intestinal parasites among the general population, particularly immunocompromised individuals producing acute or chronic diarrhea. Nevertheless, B. hominis has still become dubious as its pathogenesis has not yet fully elucidated. Objective: The study aims to prove the classical findings of the theoretical background, whether or not Cryptosporidium sp. and B. hominis are associated with immunocompromised conditions. Materials and methods: The cross-sectional study enrolled 52 participants, then divided into two groups: HIV positive (29 patients) and healthy individuals (23 patients) who involuntarily provide their feces for microscopic parasitic examination in the Department of Parasitology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia. All data were presented in bivariate mode to undergo further statistical analysis using the chi-square test. Results: There are descriptive findings proving that B. hominis is found mostly among HIV positive (7 samples), while only two positive samples are in the immunocompetent group, yet no significant association between the infection and HIV status has been obtained (p = 0.144; OR 0.299, 95%CI 0.056- 1.608). Similarly, it was also not statistically proven that Cryptosporidium sp. infection and HIV status have a significant relationship (p = 0.197; OR 4.20, 95% CI 0.407- 43.374). Conclusions: In addition to its uncertain pathogenesis, B. hominis still becomes a neglected parasitic infection among the HIV population, while Cryptosporidium sp. is confounded by other factors, mainly the CD4 count of each individual for the infection to occur.
Downloads
References
[1] Rossle NF, Latif B. Cryptosporidiosis as threatening health problem: a review. Asian Pacific journal of
tropical biomedicine. 2013 Nov 1;3(11):916-24.
[2] Wang RJ, Li JQ, Chen YC, Zhang LX, Xiao LH. Widespread occurrence of Cryptosporidium infections in
patients with HIV/AIDS: epidemiology, clinical feature, diagnosis, and therapy. Actatropica. 2018 Nov 1;
187: 257-63.
[3] Mirzaei M. Prevalence of Cryptosporidium sp. infection in diarrheal and non-diarrheic humans in Iran. The
Korean journal of parasitology. 2007 Jun;45(2):133.
[4] Odeniran PO, Ademola IO. Epidemiology of Cryptosporidium infection in different hosts in Nigeria: A
meta-analysis. Parasitology International. 2019 Aug 1;71:194-206.
[5] Stensvold CR, Clark CG. Current status of Blastocystis: a personal view. Parasitology international. 2016
Dec 1;65(6):763-71.
[6] Stark D, Barratt JL, Van Hal S, Marriott D, Harkness J, Ellis JT. Clinical significance of enteric protozoa in
the immunosuppressed human population. Clinical microbiology reviews. 2009 Oct 1;22(4):634-50.
[7] Cherry J, Demmler-Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ. Feigin and Cherry's Textbook of
Pediatric Infectious Diseases E-Book. Elsevier Health Sciences; 2013 Oct 5.
[8] A Rascon A, H McKerrow J. Synthetic and natural protease inhibitors provide insights into parasite
development, virulence, and pathogenesis. Current medicinal chemistry. 2013 Aug 1;20(25):3078-102.
[9] Beyhan YE, Yilmaz H, Cengiz ZT, Ekici A. Clinical significance and prevalence of Blastocystishominis in
Van, Turkey. Saudi medical journal. 2015 Sep;36(9):1118.
[10] Assefa S, Erko B, Medhin G, Assefa Z, Shimelis T. Intestinal parasitic infections in relation to HIV/AIDS
status, diarrhea, and CD4 T-cell count. BMC infectious diseases. 2009 Dec;9(1):155.
[11] Nissapatorn V, Sawangjaroen N. Parasitic infections in HIV-infected individuals: diagnostic & therapeutic
challenges. The Indian journal of medical research. 2011 Dec;134(6):878.
[12] Scanlan PD. Blastocystis: past pitfalls and future perspectives. Trends in parasitology. 2012 Aug
1;28(8):327-34.
[13] Ethelberg S, Lisby M, Vestergaard LS, Enemark HL, Olsen KE, Stensvold CR, Nielsen HV, Porsbo LJ,
Plesner AM, Mølbak K. A foodborne outbreak of Cryptosporidium hominis infection. Epidemiology &
Infection. 2009 Mar;137(3):348-56.
[14] Albrecht H, Stellbrink HJ, Koperskl K, Greten H. Blastocystishominis in human immunodeficiency virus-related diarrhea. Scandinavian journal of gastroenterology. 1995 Jan 1;30(9):909-14.
[15] Zhang SX, Kang FY, Chen JX, Tian LG, Geng LL. Risk factors for Blastocystis infection in HIV/AIDS patients with highly active antiretroviral therapy in Southwest China. Infectious diseases of poverty. 2019 Dec 1;8(1):89.
[16] Darlan DM, Rozi MF, Saragih RH. Cryptosporidium sp. findings in AIDS patients: A case report. Stem Cell Oncology. 2018 Apr 27:189-92
[17] Davies AP, Chalmers RM. Cryptosporidiosis. BMJ. 2009 Oct 19;339:b4168.
[18] Checkley W, White Jr. AC, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, Fayer R, Griffiths JK, Guerrant RL, Hedstrom L, Huston CD. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. The Lancet Infectious Diseases. 2015 Jan 1;15(1):85-94.
[19] Rescigno M. The intestinal epithelial barrier in the control of homeostasis and immunity. Trends in immunology. 2011 Jun 1;32(6):256-64.
[20] Reijasse D, de Serre NP, Canioni D, Huerre M, Haddad E, Leborgne M, Blanche S, Brousse N. Cytotoxic T cells in AIDS colonic cryptosporidiosis. Journal of clinical pathology. 2001 Apr 1;54(4):298-303.
[21] Leitch GJ, He Q. Cryptosporidiosis—an overview. Journal of biomedical research. 2011 Jan 1;25(1):1-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
